Biswas Saptarshi, Badiuddin Faruq
Department of General Surgery, Stanford University Medical Center, 300 Pasteur Drive, Palo Alto, CA- 94305, USA.
Cases J. 2008 Nov 17;1(1):313. doi: 10.1186/1757-1626-1-313.
: Radiation therapy (XRT) is an important modality for treatment of breast cancer. Its use has occasionally resulted in the development of secondary malignancies.We describe this interesting case of a 46-year-old woman who developed malignant fibrous histiocytoma in the contralateral breast 6 years after a lumpectomy followed by radiation therapy for infiltrating ductal carcinoma. The role of XRT in the treatment of breast carcinoma and development of Radiation induced Sarcoma (RIS) is examined.RIS has a current incidence of 0.03% to 0.2% in patients undergoing XRT for breast carcinoma. The role of XRT in the development of RIS has been clearly demonstrated. Clinical presentations vary, and diagnosis is commonly delayed. Treatment consists of wide surgical excision. Development of RIS has an average latency of over 10 years and correlates with the dose and technique of XRT. Breast conserving surgery followed by irradiation is becoming increasingly popular leading to an increasing number of sarcomas. Because of post-irradiation changes, detection of a new lesion is difficult, resulting in delayed diagnosis and poor prognosis in these patients. However, the benefit of XRT far outweighs the risk of RIS and should not affect the decision to treat these patients with this modality.
放射治疗(XRT)是乳腺癌治疗的重要手段。其应用偶尔会导致继发性恶性肿瘤的发生。我们描述了这样一个有趣的病例:一名46岁女性在因浸润性导管癌接受肿块切除术后放疗6年,对侧乳房发生了恶性纤维组织细胞瘤。本文探讨了XRT在乳腺癌治疗及放射性肉瘤(RIS)发生中的作用。接受乳腺癌XRT治疗的患者中,RIS的当前发病率为0.03%至0.2%。XRT在RIS发生中的作用已得到明确证实。临床表现各异,诊断通常会延迟。治疗包括广泛的手术切除。RIS的发生平均潜伏期超过10年,且与XRT的剂量和技术相关。保乳手术加放疗越来越普遍,导致肉瘤数量增加。由于放疗后的改变,新病灶的检测困难,导致这些患者诊断延迟且预后不良。然而,XRT的益处远大于RIS的风险,不应影响对这些患者采用这种治疗方式的决策。